# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Biolase (OTC:BIOL) with a Buy and lowers the price target from $3.5 to $2.
Benchmark analyst Bruce Jackson reiterates Biolase (OTC:BIOL) with a Speculative Buy and maintains $0.4 price target.